The growing eye industry is something investors can’t ignore.
News & Analysis: Ocular Therapeutix
OCUL earnings call for the period ending December 31, 2018.
The company reported second-quarter 2018 financial results and an important business update.
The FDA rejected its eye-pain treatment for the second time.
The biopharma thinks it just fixed its problems with the FDA.
A negative article by STAT has investors worried about the approvability of the biotech's eye drug.
Presentation of positive phase 3 data sent shares higher.
The FDA wants some changes at the biotech's manufacturing plant.
Positive patient experience for the company's eye insert, Dextenza, sends shares higher.
An analyst upgrade ahead of an FDA decision for its eye-pain medication sends shares higher.